Drug Type Small molecule-drug conjugates |
Synonyms QHL-108 |
Target |
Action inhibitors |
Mechanism DNA intercalators, Top II inhibitors(Topoisomerase II inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC48H64N6O18 |
InChIKeyMXJIXMIBWBRASS-UGZZBAIUSA-N |
CAS Registry606967-53-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Soft Tissue Sarcoma | Phase 3 | - | - | |
Non-squamous non-small cell lung cancer | Phase 2 | China | 20 Mar 2025 | |
Adenocarcinoma of Lung | Phase 2 | - | - | |
Breast Cancer | Phase 2 | China | - | |
Advanced Malignant Solid Neoplasm | Phase 1 | China | 14 May 2020 | |
Choriocarcinoma | IND Approval | China | 03 Mar 2025 | |
Ovarian Cancer | IND Approval | China | 03 Mar 2025 | |
Advanced Lung Non-Small Cell Carcinoma | IND Approval | China | 26 Aug 2024 | |
metastatic non-small cell lung cancer | IND Approval | China | 26 Aug 2024 | |
Glioma | IND Approval | China | 28 Jun 2023 |